ATE336240T1 - Therapeutische verwendung von stickstoffmonoxydinhibitoren - Google Patents

Therapeutische verwendung von stickstoffmonoxydinhibitoren

Info

Publication number
ATE336240T1
ATE336240T1 AT97952182T AT97952182T ATE336240T1 AT E336240 T1 ATE336240 T1 AT E336240T1 AT 97952182 T AT97952182 T AT 97952182T AT 97952182 T AT97952182 T AT 97952182T AT E336240 T1 ATE336240 T1 AT E336240T1
Authority
AT
Austria
Prior art keywords
tissue
inhibitor
cells
population
bone marrow
Prior art date
Application number
AT97952182T
Other languages
English (en)
Inventor
Grigori Enikolopov
Natalia I Peunova
Boris Kuzin
Hollis Cline
Tatiyana Michurina
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of ATE336240T1 publication Critical patent/ATE336240T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97952182T 1996-11-13 1997-11-13 Therapeutische verwendung von stickstoffmonoxydinhibitoren ATE336240T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3069096P 1996-11-13 1996-11-13
US4541197P 1997-05-02 1997-05-02

Publications (1)

Publication Number Publication Date
ATE336240T1 true ATE336240T1 (de) 2006-09-15

Family

ID=26706342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97952182T ATE336240T1 (de) 1996-11-13 1997-11-13 Therapeutische verwendung von stickstoffmonoxydinhibitoren

Country Status (7)

Country Link
US (2) US5977181A (de)
EP (1) EP0952828B1 (de)
AT (1) ATE336240T1 (de)
AU (1) AU5585598A (de)
CA (1) CA2271729A1 (de)
DE (1) DE69736526T2 (de)
WO (1) WO1998020865A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593372B2 (en) 1996-11-13 2003-07-15 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
ATE336240T1 (de) 1996-11-13 2006-09-15 Cold Spring Harbor Lab Therapeutische verwendung von stickstoffmonoxydinhibitoren
AU8647198A (en) * 1997-08-12 1999-03-01 Chugai Seiyaku Kabushiki Kaisha Remedies for diseases associated with bone resorption
US6589759B1 (en) 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
CA2374209A1 (en) * 1999-05-20 2000-11-30 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
AU2003218099A1 (en) * 2002-03-12 2003-09-29 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
WO2008034929A1 (es) * 2006-09-19 2008-03-27 Fundación Progreso Y Salud Método para el cultivo y mantenimiento de células troncales pluripotenciales y de células progenitoras de mamífero en estado no diferenciado
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
US8470857B2 (en) * 2008-08-15 2013-06-25 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
ES2572615T3 (es) 2008-08-15 2016-06-01 Nivalis Therapeutics, Inc. Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
MX374075B (es) 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2013006635A1 (en) * 2011-07-05 2013-01-10 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents for liver toxicity
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
KR20230119259A (ko) 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510745A (ja) * 1993-05-20 1996-11-12 リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド 骨髄前駆体細胞増殖および敗血症ショックの処置のためのペプチド
JPH07316023A (ja) * 1994-05-26 1995-12-05 Shiseido Co Ltd 育毛料
ATE336240T1 (de) 1996-11-13 2006-09-15 Cold Spring Harbor Lab Therapeutische verwendung von stickstoffmonoxydinhibitoren

Also Published As

Publication number Publication date
US5977181A (en) 1999-11-02
DE69736526D1 (de) 2006-09-28
AU5585598A (en) 1998-06-03
EP0952828A2 (de) 1999-11-03
US20030119905A1 (en) 2003-06-26
WO1998020865A3 (en) 1998-07-23
EP0952828B1 (de) 2006-08-16
US6809117B2 (en) 2004-10-26
WO1998020865A2 (en) 1998-05-22
CA2271729A1 (en) 1998-05-22
DE69736526T2 (de) 2007-04-26

Similar Documents

Publication Publication Date Title
ATE336240T1 (de) Therapeutische verwendung von stickstoffmonoxydinhibitoren
NO20041844L (no) Peptider som er effektive i behandlingen av tumorer og andre tilstander i forbindelse med fjerning eller odeleggelse av celler
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
ES551761A0 (es) Un procedimiento para la preparacion de un vector de dna recombinante
DE69033975D1 (de) Rekombinanttherapien für Infektionen und hyperproliferative Störungen
Barret et al. Outcome of scalp donor sites in 450 consecutive pediatric burn patients
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69518760D1 (de) Wachstumsdifferenzierungsfaktor-12
SE8902532D0 (sv) Bestaemning av plasmaproteiner
RU94022017A (ru) Способ лечения акне или псевдофолликулита бороды, способ получения композиции, применение ингибитора фермента орнитиндекарбоксилазы для лечения акне или псевдофолликулита бороды
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
EA200001124A1 (ru) Способ генной терапии
DE69332373D1 (de) Menschlicher epidermaler Gen-Promotor
DE69528473D1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE50004024D1 (de) Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation
SU628904A1 (ru) Способ обезболивани
Kilburn et al. Connective Tissue of the Lung: Introduction
WO2002016419A3 (en) Progression suppressed gene 13 (psgen 13) and uses thereof
Simon et al. Increased hair growth and density following controlled expansion of guinea pig skin and soft tissue
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
Steinmann et al. Collagen disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties